Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.
The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.
Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.
Inovio Pharmaceuticals (INO) said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.
Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.
Candel Therapeutics (CADL) sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.
More than 15.1 million shares traded intraday compared with a daily average of about 2.4 million.
Price: 1.71, Change: -2.26, Percent Change: -56.95
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。